-+ 0.00%
-+ 0.00%
-+ 0.00%

ProMIS Highlights Alzheimer's & Dementia Publication Linking Preferential Targeting Of Soluble Toxic Aβ Oligomers To Efficacy And Lower ARIA Risk

Benzinga·12/10/2025 12:46:21
Listen to the news
  • Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque 
  • ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer's disease by end of 2025 with planned Q2 2026 interim readout